To the Editor We read with great interest the review by Cook and Kim1 recently published in JAMA Oncology. We commend the authors for addressing a timely public health issue—the safety and efficacy of immune checkpoint inhibitor therapy among patients with HIV and advanced-stage cancer. Despite this review’s scientific contribution to the literature, methodological issues in the article raise questions on its validity and reproducibility.